Significantly lower risk is seen for mortality, hospitalization, progression, and recovery. 10 studies from 7 independent teams (all from the same country) show significant benefit.
Meta analysis using the most serious outcome reported shows 63% [51‑71%] lower risk. Results are similar for higher quality studies and worse for Randomized Controlled Trials.
Results are very robust — in exclusion sensitivity analysis 9 of 11 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2, BA.4, BA.51, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.12. mAb use may create new variants that spread globally3,4, and may be associated with prolonged viral loads, clinical deterioration, and immune escape4-7.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Dec 2024, preprint, 1 author.
